At Harvard’s Wyss Institute, a multidisciplinary team used AI-enabled dynamic molecular modeling, inspired by film industry animation techniques, to repurpose and optimize antiviral agents with broad activity against respiratory coronaviruses. Starting from the FDA-approved drug bemcentinib, the group developed optimized compounds targeting multiple variants, addressing emergent virus resistance and pandemic preparedness. This pipeline integrates computational and biological modeling to accelerate oral antiviral drug discovery for coronavirus infections replacing vaccine-only strategies facing global accessibility and efficacy challenges.